Castration-resistant prostate cancer (CRPC) continues to be a major clinical problem and the mechanisms behind it remain unclear. Thioredoxin domain-containing protein 5 (TXNDC5) is involved in protein folding and chaperone activity, and its overexpression has been reported in multiple malignancies. In the current study, we demonstrated that TXNDC5 is up-regulated following longterm androgen-deprivation treatment (ADT) and is highly overexpressed in CRPC tumors compared with hormone-naive prostate cancer (PCa) cases. Functionally, in vitro and in vivo studies demonstrated that TXNDC5 overexpression promotes the growth of both androgen-dependent and castration-resistant PCa xenografts. Mechanistically, TXNDC5 directly interacts with the AR protein to increase its stability and thus enhances its transcriptional activity. TXDNC5-mediated CRPC growth can be fully abolished by AR inhibition, suggesting TXDNC5 up-regulation as an escape pathway for aberrant AR re-activation and CRPC growth in the milieu of low androgen. Indeed, we found that TXNDC5 is increased by ADT-induced hypoxia through HIF-1α in an miR-200b-dependent manner. Overall, we defined an important role of TXNDC5 in CRPC and further investigations are needed to screen TXNDC5 antagonists as a novel therapeutic approaches to treat PCa patients with CRPC.
INTRODUCTION
Prostate cancer (PCa) is the second leading malignancy in men worldwide, and its incidence has been increasing continuously in recent years. 1 Androgen and androgen receptor (AR) play critical roles in PCa development and progression. 2 To date, androgendeprivation treatment (ADT) remains the standard first-line therapy for patients with hormone-dependent (HD) PCa. 2 However, patients invariably relapse with the more aggressive castration-resistant prostate cancer (CRPC) within 18-24 months. 3, 4 The mechanisms by which androgen signaling is altered in CRPC are either AR-dependent-such as AR mutation/ amplification, intratumoral production of androgens, modified expressions of coactivators/corepressors and dysregulation of ARregulated genes-or AR-independent. 4 Hormonal therapies that target androgen biosynthesis (for example, Abiraterone) or the AR directly (for example, Enzalutamide) improve outcomes for patients with CRPC, but they are not universally effective and responses are not durable. 5 Therefore, identification of key molecules to interact with AR and development of novel strategies to target CRPC are urgently needed.
Thioredoxins are a group of small ubiquitous proteins that are key regulators of cellular redox balance. 6 Overexpression of these proteins in cancer may be associated with aggressive tumor growth and poor survival. 7 Several inhibitors of the thioredoxin system, such as PX-12 and SAHA, have been evaluated in experimental cancer models or clinical trials. 8, 9 Thioredoxin domain-containing protein 5 (TXNDC5) is a member of the thioredoxin family involved in protein folding and chaperone activity. 10 Overexpression of TXNDC5 has been reported in several malignancies including cervix, colon, stomach, prostate, liver and lung. 11 Wei et al. 12 used transcriptome profiling to demonstrate a higher level of TXNDC5 in androgen-independent (AI) than in androgen-dependent PCa tissues. However, the exact role of TXNDC5 in CRPC has not yet been investigated. In the current study, we show that TXNDC5 overexpression could induce and promote a CRPC-like phenotype through activation of AR signaling. We also demonstrate that ADT-induced hypoxia could strengthen the interaction between TXNDC5 and AR and regulate the expression of TXNDC5 through an miR-200b-dependent pathway.
RESULTS
TXNDC5 is up-regulated in castration-resistant prostate cancer To begin to understand the role of TXNDC5 in PCa, immunohistochemical staining and quantification were performed in PCa samples. Totally, 94 clinical samples of HD (n = 71) and CRPC (n = 23) PCa were successfully stained. TXNDC5 was detected predominantly in cytoplasm; protein levels were greater in cancer cells than in adjacent benign prostatic hyperplasia (data not shown). Further, among HD tumors, 46 (65.5%) showed negative or weak staining (score 0-1), and only 25 (35.5%) had moderate or strong staining (score 2-3) for TXNDC5. For the CRPC tumors, however, 16 (69.6%) samples showed moderate to strong expression, whereas only 7 (30.4%) were negative or weak. Representative immunohistochemistry (IHC) images of TXNDC5 are shown in Figure 1a . Overall, castration-resistant tumors showed significantly stronger expression of TXNDC5 than HD tumors (Pearson's = 0.672, P = 0.017, Figure 1b ). Further, we established an AI LNCaP cell line, LNCaP-AI, which rapidly produces tumors in castrated nude mice ( Supplementary  Figures 1a and b ). Notably, chronic androgen deprivation could also significantly induce TXNDC5 expression ( Figure 1c ), which corroborates the IHC results and further indicates a potential role of TXNDC5 in CRPC.
TXNDC5 contributes to abnormal proliferation and invasion of PCa cells in vitro and in vivo
The expression levels of TXNDC5 in PCa cell lines are shown in Supplementary Figure 2a . MTT assay showed that silencing TXNDC5 could significantly inhibit the proliferation of multiple PCa cell lines (Figure 2a ). In contrast, forced TXNDC5 expression in LNCaP cells (LNCaP-TXNDC5) promoted growth faster than the control cells transfected with empty vector (LNCaP-VC) in vitro ( Figure 2b ) in the presence of androgen. Additionally, in vivo experiments demonstrated that the growth rate of LNCaP-TXNDC5-derived tumors was faster than LNCaP-VC-derived tumors after 2 weeks of inoculation, and the final tumor volumes were 2250 mm 3 and 816 mm 3 (Figures 2c and d) , respectively. Also, as shown in Figure 2a and Supplementary Figure 2b , the inhibitory effect of silencing TXNDC5 on cellular proliferation was 39% in LNCaP-AI cells than that in LNCaP cells (27%) (P = 0.037). Flow cytometry DNA analysis further demonstrated that silencing TXNDC5 leads to a significant accumulation of PCa cells in the S phase and fewer cells in the G2/M phase ( Supplementary Figure 2c ).
Next, we evaluated the effect of TXNDC5 on the invasive capacity of PCa cells using Transwell apparatus in vitro. As shown in Figure 2e , silencing TXNDC5 decreased invasion of VCaP (e1-4), PC3 (e5-8) and LNCaP-AI (e9-12) cells (for both P o0.05), whereas LNCaP-TXNDC5 showed an increased percentage of migrated cells (P o 0.05, Figure 2e , [13] [14] . Interestingly, prostate-specific antigen (PSA) secretion levels were significantly altered after up-or downregulation of TXNDC5 in vivo (Supplementary Figure 3a ) and in vitro ( Supplementary Figure 3b ), respectively. Taken together, these results support the hypothesis that TXNDC5 may exert tumor-promoting effects in PCa.
TXNDC5 overexpression induces a CRPC-like phenotype
Next, we investigated whether TXNDC5 overexpression contributes to castration-resistant tumor growth. As shown in Figure 3a The study cohorts were assembled onto two tissue microarrays with an average of two cores per patient using a manual tissue arrayer. Each block was assembled without prior knowledge of any clinical or pathological staging information. For IHC, the slides were incubated with the anti-TXNDC5 antibody overnight at 4°C (1:100 dilution, Abcam). The slides were then evaluated blindly by two independent observers (B.H. and W.T.) who were blind to the clinicopathologic data. The staining intensity (range, 0-3) and the percentage of positive cells (range, 0-4 (0, (0-10%), 1(11-25%), 2(26-50%), 3(51-75%), and 4 (76-100%))) were multiplied. A final score was built by multiplying the scores of these two parameters, which are defined in the following way: 0, negative; 1-3, weak; 4-6, moderate; and 8-12, strong. For analysis, we combined both negative and weakly TXNDC5 positive tumors into one group and compared it with moderately and strongly TXNDC5-positive PCas. The TXNDC5 IHC in human PCa tissues, × 200 magnification. The staining intensity of TXNDC5 in clinical cases of PCa was graded as weak (a1), moderate (a2) and strong (a3). (b) Percentages of different TXNDC5 expression levels in HD and AI tumors. (c) An AI subline was established by continuously culturing the LNCaP cells in medium with 10% FBS depleted of steroids for 6 months and was labeled as LNCaP-AI. Expression of TXNDC5, AR and HIF-1α were detected by western blot in LNCaP-AI and LNCaP, respectively.
TXNDC5 and castration-resistant prostate cancer L Wang et al phenotype. 13 We apllied western blot and found that TXNDC5 overexpression sensitizes PCa cells to the activation of AKT, ERK1/2 and HER2 in response to androgen stimulation at a very low level ( Figure 3e ), as well as AKT, ERK1/2 and MET after CoCl 2 -induced hypoxia stimulation ( Figure 3f ). These data imply that increased TXNDC5 levels protect androgen-dependent PCa cells from the treatment stress induced by androgen withdrawal and facilitate AI tumor progression after castration.
Identification of HSP70 and AR as novel TXNDC5-interacting proteins
To address how TXNDC5 promotes CRPC in PCa, we coupled parallel co-immunoprecipitation (co-IP) and mass spectrometry to identify TXNDC5-interacting proteins ( Figure 4a ). The protein bands that were pulled down from HA-TXNDC5-expressing cells ( Figure 4a , lanes 2) but not the empty vector-transfected cells ( Figure 4a , lanes 1) were excised from the blot for further analysis by mass spectrometry. HSP70 and AR were present in the 70/110-kDa band (Figure 4a ). The endogenous interactions between them were further verified by co-IP in LNCaP and VCaP (Supplementary Figure 4a ) cells, respectively. No endogenous binding was identified between AR and HSP70 in PCa cells.
TXNDC5 interacts directly with AR, but indirectly with HSP70 We next examined the ability of hTXNDC5-GST fusion proteins to interact with HSP70 and AR in vitro. Bacterially expressed hTXNDC5-GST was mixed with human ectopically expressed AR synthesized by HEK293T cells or extracts from LNCaP cells expressing AR in vitro.
After GST pull-down, AR was observed to bind with the TXNDC5-GST fusion protein by western analysis using anti-AR antibodies, but did not bind with GST alone (Figure 4b ). However, no direct interaction was detected between HSP70 and TXNDC5 (data not shown). Thus, these GST pull-down experiments further confirmed the endogenous co-IP experiments, demonstrating that TXNDC5 interacts directly with AR, but indirectly with HSP70.
Castration resistance induced by TXDNC5 overexpression can be blocked by anti-AR, but not anti-HSP70, signaling To identify which pathway is critical for the function of TXDNC5 in PCa, we evaluated the effects of Enzalutamide, an AR antagonist that binds AR to prevent its nuclear translocation and recruitment to chromatin, 14 3 ) were castrated 7 days after inoculation and randomized into two groups (n = 10 mice per group). Subcutaneous xenograft assay was applied to monitor tumor growth formed by LNCaP-VC and LNCaP-TXNDC5 cells in castrated mice. (d) To analyze circulating total PSA levels from the tumor implant in castrated mice, blood samples were collected from the tail veins once a week post castration. For both (e and f), western blot analysis was performed to determine the phosphorylation and total levels of Akt (S473), ERK1/2, MET, Her2 under ADT or hypoxic conditions. Band intensity given underneath gel images was measured using ImageJ software (NIH, Bethesda, MD, USA) and presented as fold change compared with 0 min timepoint. GAPDH was used as loading control. *P o0.05; **P o0.01.
overexpression resulted in a significant increase in the AR protein half-life, indicating that TXNDC5 may exert a chaperone effect on AR protein stabilization.
Previous studies showed that AR forms a heterodimer complex with HSP90 to protect ligand-unbound AR from degradation by the ubiquitin-proteasome system. 15 Here, we observed that silencing TXNDC5 significantly disrupts the association between AR and HSP90 by western blot (Figure 5e ). Interestingly, a significant increase in AR nuclear translocation was identified by western assay following TXNDC5 overexpression after androgen (Figures 5f and g) . Together, these data indicate that TXNDC5 protects AR from degradation and promotes its nuclear translocation to facilitate its activity.
TXNDC5 positively regulates AR activity
We hypothesized that TXNDC5 overexpression enhances AR function and thereby facilitates the AI phenotype. As shown in Figure 6a , exogenous TXNDC5 expression resulted in a dosedependent enhancement of androgen-stimulated transcription from a reporter gene containing the 6-kb PSA promoter (PSA-Luc; Figure 6a ) by luciferase reporter gene assay. Next, we tested androgen induction of AR-regulated genes and found, by real-time PCR, that TXNDC5 overexpression enhanced the expression of the gene encoding PSA in a dose-dependent manner (Figure 6b ). Accordingly, overexpression of TXNDC5 led to substantial inductions in the transcript levels for the TMPRSS2, KLK2, S100P and FKBP51 genes (Figure 6c ). 16 These data provide clear evidence that TXNDC5 contributes to the regulation of AR activity in PCa.
TXNDC5 expression enhances AR responsiveness to diverse ligands Next, we analyzed whether overexpression of TXNDC5 alters ARdependent transcription in response to several AR-binding ligands. TXNDC5 stimulated AR transcriptional activity in the presence of Enzalutamide and flutamide (Figure 6d ). TXNDC5 also stimulated AR activity in the presence of high concentrations of estrogen (Figure 6d ). These results prompted us to explore whether TXNDC5 affects the efficacy of Enzalutamide. We tested this by measuring AR transcriptional activity in the presence of dihydroxytestosterone and a range of Enzalutamide concentrations. AR became resistant to maximal inhibition by Enzalutamide (Figure 6e ). Thus, TXNDC5 overexpression promotes AR activity in response to a variety of ligands and has the potential to influence the efficacy of anti-androgens used in PCa treatment.
ADT-induced hypoxia enhances the TXNDC5-AR interaction A previous study showed that long-term ADT-induced hypoxia could enhance the transcriptional activity of AR through hypoxia-inducible factor-1α (HIF1α) to promote CRPC. 17 Further, we have shown that hypoxia can induce TXNDC5 expression in rheumatoid arthritis. 18 On the basis of our results, we hypothesized that ADT-induced hypoxia could affect the interaction between TXNDC5 and AR to facilitate CRPC progression. As shown in Figure 1c , significantly higher TXNDC5, AR and HIF-1α levels were observed in LNCaP-AI cells. Interestingly, co-IP analysis showed that the binding activity between TXNDC5 and AR was significantly higher in LNCaP-AI compared with LNCaP cells (Figure 7a ). Further, inducing hypoxia with CoCl 2 led to the upregulation of TXNDC5 and AR expression ( Figure 7b ) and enhanced their interaction in LNCaP cells (Figure 7c ). Importantly, silencing HIF-1α inhibited TXNDC5 expression at both mRNA and protein levels in PC3 and LNCaP-AI cells ( Supplementary  Figure 6a ), but TXNDC5 was not a direct target of HIF-1α, as demonstrated by luciferase activity assay ( Supplementary  Figure 6b ). Collectively, these data further corroborate important roles of TXNDC5 in CRPC, and its interaction with AR may be another pivotal pathway through which ADT-induced hypoxia exacerbated PCa progression.
miR-200b directly mediates hypoxia-induced TXNDC5 expression
To further characterize how hypoxia induces TXNDC5 expression in PCa, we applied TargetScan prediction software (http://www. targetscan.org) and revealed that the TXNDC5 3′-UTR mRNA has a Figure 6c ). Previously, it had been shown HIF-1α stabilization is responsible for the downregulation of miR-200b under hypoxic conditions. 19 Additionally, miR-200b levels were significantly decreased by androgen deprivation and hypoxia treatments in multiple PCa cells (Figure 7d ). In contrast, silencing HIF-1α upregulates the expression of miR-200b ( Supplementary  Figure 6d ), which suggests that HIF-1α/miR-200b may coparticipate in PCa progression. Indeed, our western blot results showed that miR-200b regulated TXNDC5 protein level in different PCa cell lines (Figure 7e ). Further, miR-200b regulated the luciferase activity of the wild-type TXNDC5 3′-UTR reporter (Figure 7f ), and the effects were abolished with its mutant reporter. These findings suggest that miR-200b attenuates TXNDC5 expression through direct targeting of the predicted 3′-UTR. Notably, the miR-200b mimic treatment significantly blunted hypoxia-induced TXNDC5 upregulation (Figure 7g) , which indicated that a miR-200b-dependent mechanism exists to regulate hypoxia-induced TXDNC5 expression. In total, these results demonstrate that miR-200b mediates HIF1α-induced TXNDC5 expression under ADT conditions, although the exact roles of miR-200b in CRPC merits further investigation.
DISCUSSION
This is the first study to systematically characterize the role of TXNDC5 in CRPC. Aberrant TXNDC5 expression has been reported in multiple malignancies, probably representing an early event in the progression of colon 20 and lung cancers. 21 Consistent with a previous report, 12 our study showed that TXNDC5 expression is higher in CRPC than in localized PCa tissues. Accordingly, longterm ADT also induced higher TXNDC5 expression in LNCaP cells. Functional analyses further demonstrated that TXNDC5 promotes the proliferation of PCa cells in vitro and in vivo, partly because of the dysregulation of cell cycles between G2/M and S phases. Similar results were also reported in gastric cancer cells 22 and rheumatoid arthritis synovial fibroblasts. 18 Further studies showed that overexpression of TXNDC5 provides a survival advantage for LNCaP cells under androgen-deprived or castration conditions. Interestingly, TXNDC5 was also upregulated in chemo-resistant xenografts of PCa after cyclophosphamide therapy, 23 and TXNDC5 silencing exhibited more apparent inhibitory effects on the proliferation of LNCaP-AI than in LNCaP in vitro. In total, these data suggest a critical role of TXNDC5 during PCa progression.
To address how TXNDC5 contributes to CRPC, direct interaction was identified between TXNDC5 and AR, but not between TXNDC5 and HSP70. Importantly, RNAi-AR or Enzalutamide treatment almost abolished the function of TXDNC5 in promoting proliferation and invasion in vitro and delayed CRPC progression in vivo, which strongly indicated that AR signaling was critical to the function of TXNDC5. Previous studies suggested that HSP70 is a stress-inducible HSP that promotes survival and invasion of PCa, and inactivation of HSP70 leads to the loss of invasion in various cancer cell types. 24 Although the HSP70 inhibitor KNK437 produced no visible effects on the function of TXNDC5 overexpression in PCa cells ( Supplementary Figures 5a and b) , silencing HSP70 ( Supplementary Figure 5c ) or KNK437 treatment ( Supplementary Figures 5d and e ), which has been shown to interfere with transcriptional activation of HSP70, 25 could decrease TXNDC5 protein expression through reducing the half-time of TNXDC5 protein ( Supplementary Figure 5f ). Their interaction further supports the pro-metastasis function of TXNDC5.
Previous studies revealed that AR, still expressed in most CRPC, is hyperactive, 26 and the AR signaling axis together with its interactive proteins remain the focus for effective therapeutic regimens for CRPC. Thioredoxin family members have been shown to regulate transcription factor activity in human tumors. 27, 28 In addition, TXNDC5 may function to regulate the activity of its partners, such as AdipoR1. 29 In this study, we provided several lines of evidence to show that TXNDC5 may regulate the activity of AR signaling during PCa progression. First, TXNDC5 could stabilize AR and promote its nuclear translocation. Second, reporter-and endogenous-gene-based assays suggested that TXNDC5 induces AR-dependent transcription. Third, TXNDC5 induces assembly of the HSP90 superchaperone complex, which is also crucial to AR functions and stability. 15 Fourth, TXNDC5 could sensitize AR responsiveness to diverse ligands and render AR resistant to Enzalutamide. Thus, increased expression of TXNDC5 could amplify AR signaling under the low-hormone conditions that occur during androgen ablation and provide survival advantages to PCa cells.
Multiple receptor tyrosine kinases, which become hypersensitive to stimuli in the tumor microenvironment, have been found to contribute to CRPC progression. Inhibition of these molecules sensitizes PCa cells to androgen withdrawal. 30 Our results suggest that Akt, ERK1/2, MET and HER2 signaling pathways in TXNDC5overexpressing PCa cells become sensitive to stimuli, such as very low amounts of androgens or hypoxia, during CRPC progression. Of them, HER2 has been suggested to stabilize AR proteins, especially after androgen withdrawal, and to increase the interaction of AR to promoter/enhancer regions of the ARregulated genes. 31, 32 In addition, the Akt signaling pathway enhances AR activity in LNCaP cells with high passage numbers, 33 all of which suggest how TXDNC5 exerts its effects on AR signaling activity in ADT conditions and further support its roles in PCa progression.
Previous studies identified that ADT-induced hypoxia in LNCaP xenografts leads to CRPC through HIF-1α. 34 Interestingly, TXNDC5 could also be induced by hypoxia and exert a protective effect on endothelial cells by inducing the activity of anti-apoptotic molecules. 11 Further, hypoxia could lead to HIF-1α-mediated AR transactivation, and AR could promote PCa progression by activating HIF-1α. 35 Here, our data showed that ADT-induced hypoxia could upregulate the expression of TXNDC5 and AR, as well as strengthen their interaction, all of which may further facilitate the effects of TXNDC5 in coordinating AR to promote CRPC. Of interest, we also found that miR-200b mediates the regulation of ADT-induced hypoxia on TXNDC5 expression. This finding not only provides a novel regulation mechanism of HIF-1α on TXNDC5 in the context of androgen deprivation, but also opens up a new avenue for addressing the posttranscriptional regulation of TXNDC5.
Taken together, our results indicate that TXNDC5 could promote PCa progression, especially CRPC, through AR signaling. Notably, their interaction could be strengthened by ADT-induced hypoxia as illustrated in Figure 7h . The identification of small molecules that selectively inhibit TXNDC5 and its binding partners could be helpful to define clinically targetable pathways to prevent and/or treat PCa patients with CRPC.
MATERIALS AND METHODS Patients
A total of 101 patients diagnosed with PCa participated in our study. The tumor samples were obtained from Qilu Hospital of Shandong University (Jinan, China) and The Affiliated Hospital of Qingdao University (Qingdao, China) between 2003 and 2007. The first cohort consisted of 76 men with localized PCas who underwent radical prostatectomy. None of the patients received preoperative radiation or ADT. The second cohort included patients with CRPC treated by transurethral resection of the prostate to relieve symptomatic obstruction due to locally advanced disease (n = 25). The initial treatment for patients was either observation or surgery. Development CRPC was treated by flutamide or bicalutamide. This study was approved by the Institutional Review Board at the school of medicine of Shandong University. The study protocol was approved by the local ethical committee, and informed consent was obtained from the patients.
Immunohistochemistry (IHC)
IHC and the scoring system were performed as previously described. 36 Briefly, the slides were incubated overnight with the anti-TXNDC5 antibody at 4°C, and were then evaluated blindly by two independent observers (B.H. and W.T.) who were blind to the clinicopathologic data. For analysis, we combined both negative and weakly TXNDC5-positive tumors into one group and compared it with moderately and strongly TXNDC5positive PCas.
Cell culture and stable transfection establishment LNCaP, VCaP, 22RV1, DU145 and PC3 cells were obtained from American Type Culture Collection (Manassas, VA, USA) and passaged for fewer than 6 months. Before experiments with hormone exposure, cells were grown in phenol red-free RPMI-1640/DMEM (Hyclone, Logan, UT, USA) supplemented with 10% charcoal/dextran-treated fetal bovine serum (Hyclone) for 72 h. The medium was then replaced with one that contained various concentrations of chemicals as shown in Supplementary Materials. To establish stable transfection, clones were selected with 400 ng/ml geneticin (G418; Invitrogen, Carlsbad, CA, USA), and those showing the highest overexpression of TXNDC5 were selected and designated as LNCaP-TXNDC5. Cells transfected with an empty vector (LNCaP-VC) were used as the control.
Plasmid constructs
Vectors inserted with the TXNDC5 and HIF-1α-coding region (full length of cDNA from H293T cell by the primers containing the BamHI/XhoI site in pcDNA3.1 and BamHI/Xbal I site in pCMV-HA) were transfected into LNCaP or HEK293T with Lipofectamine 2000 (Invitrogen). shHSP70 (V2LHS_243542) was obtained from Thermo Scientific (Pittsburgh, PA, USA). The promoter region(−2000 bp~transcription start site) and 3′-UTR of TXNDC5 gene or mRNA was amplified from HEK293T and cloned into the pGL3-basic vector using SacI and XhoI restriction sites and the pmirGLO dual luciferase reporter vector using SacI and SalI restriction sites, respectively. Mutant TXNDC5 3′-UTR was also generated on miR-200b target recognition site as shown in Figure 7g by site mutation kit (Beyotime, Beijing, China). To generate the glutathione S-transferase (GST)-TXNDC5 recombinant protein expression construct, the full-length cDNA of TXNDC5 was digested from pcDNA3.1-TXDNC5 and inserted into the
